Evogene Ltd. (EVGN)
| Market Cap | 5.60M -50.2% |
| Revenue (ttm) | 1.66M -73.1% |
| Net Income | -9.07M |
| EPS | -0.85 |
| Shares Out | 13.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,830 |
| Open | 0.3610 |
| Previous Close | 0.3610 |
| Day's Range | 0.3524 - 0.3898 |
| 52-Week Range | 0.3452 - 1.2800 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 19, 2026 |
About EVGN
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses... [Read more]
Financial Performance
In 2025, Evogene's revenue was $3.85 million, a decrease of -30.91% compared to the previous year's $5.58 million. Losses were -$8.49 million, -48.53% less than in 2024.
Financial StatementsNews
Evogene Targets Acute GVHD With AI-Driven Drug Discovery Program
(RTTNews) - Evogene Ltd. (EVGN), an AI-enabled company developing small molecules for pharmaceutical and agricultural markets, announced acute graft-versus-host disease as the target indication for it...
Evogene Ltd. Announces Acute Graft-Versus-Host Disease (aGVHD) as Target Indication for Drug Discovery Program on October 28, 2026
Evogene Ltd. announced on October 28, 2026, that it has selected acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery program. The program aims to...
Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory Patients REHOVOT, Israel, Oct. 28, 2026 /PRNe...
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain REHOVOT, Israel, Oct. 26, 2026 /PRNewswire/ -- Evogene Ltd. (NA...
Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL
The roadshow will connect leading Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partners REHOVOT, Israel, Oct. 20,...
Evogene announces cooperation agreement with Pure Capital Group
Evogene (EVGN) announced that it has entered into a comprehensive cooperation agreement with L.I.A. Pure Capital and Invest Pro Shukai Hon, together, the “Pure Capital Group”, to resolve all outstandi...
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceut...
Evogene Gets 180-day Nasdaq Extension To Regain Compliance
(RTTNews) - Israeli computational chemistry company Evogene Ltd. (EVGN), announced on Wednesday that it has received an additional 180 days from Nasdaq to regain compliance with the minimum $1 bid pri...
Evogene receives non-compliance letter from Nasdaq
Evogene (EVGN) reported that the Company received a letter from the Nasdaq Stock Market, indicating that on March 30 the Company was notified, based on the previous 30 consecutive business…
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd.
Evogene responds to latest communication from L.I.A. Pure Capital, Invest-Pro
Evogene (EVGN) responded to the latest communication from dissident shareholders L.I.A. Pure Capital and Invest-Pro. “The dissidents focus heavily on Evogene’s historical performance and call for a wh...
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
Company urges shareholders to evaluate the significant changes already implemented and vote FOR all Evogene nominees on September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 31, 2026 /PRNews...
EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN), is pleased to report the voting results from its Annual General Meeting of Shareho...
Evogene (EVGN) Q2 2026 Earnings Call Transcript
AI-driven computational chemistry platform advances pharma partnerships while cutting cash burn.
Evogene’s director nominees recommended by ISS and Glass Lewis
Evogene (EVGN) announced that independent proxy advisory firms ISS and Glass Lewis have recommended that Evogene shareholders vote “for” the company slate of nominees in connection with the September ...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
Recommendations Reinforce Confidence in Evogene's Strategic Plan and Long-Term Value Creation Strategy Board Urges Shareholders to Vote FOR All Evogene Nominees, and to disregard the Pure Capital Nom...
Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35%
Evogene Ltd. delivered a surprise narrowing of its quarterly loss, beating consensus expectations by 50% despite posting a 35% revenue decline. The biotechn... The post Evogene Q2 2026 Deep Dive: EPS ...
Evogene Q2 Loss Narrows As AI Transformation Drives Strategic Progress
(RTTNews) - Evogene Ltd. (EVGN) reported second-quarter and first-half 2026 financial results, highlighting continued progress in its transformation into a focused, AI-driven computational chemistry c...
Evogene Earnings Call Transcript: Q2 2026
Transformation to an AI-driven model led to reduced costs, improved Q2 net loss, and progress in pharma and ag pipelines. Monetization of non-core assets and new collaborations support a stronger financial position and outlook. Cash usage remains disciplined.
Evogene Earnings release: Q2 2026
Evogene released its Q2 2026 earnings on August 18, 2026, summarizing the period's financial results.
Evogene Reports Second Quarter and First Half 2026 Financial Results
Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product devel...
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemist...
Evogene Schedules Second Quarter 2026 Financial Results Release
Zoom conference call scheduled for August 18, 2026, 9:00 AM ET REHOVOT, Israel, July 30, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry,...
Evogene and ELEO announce scientific collaboration
Evogene (EVGN) and ELEO, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, announced a strategic scientific collaboration to ...
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billio...